Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.

Cancer research - 1 Apr 2005

Kambara Hirokazu, Okano Hideyuki, Chiocca E Antonio, Saeki Yoshinaga

Abstract excerpt

Oncolytic herpes simplex virus-1 (HSV-1) mutants possessing mutations in the ICP34.5 and ICP6 genes have proven safe through clinical trials. However, ICP34.5-null viruses may grow poorly in cells due to their inability to prevent host-cell shut-off of protein synthesis caused by hyperphosphorylation of eukaryotic initiation factor 2alpha. To increase tumor selectivity, glioma-selective expression of ICP34.5 in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Eukaryotic Initiation Factor-2

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Glioma

Share to Herpesvirus 1, Human

Share to Immunoblotting

Share to Intermediate Filament Proteins

Share to Mice, Nude

Share to Nestin

Source

Identifiers

PMID: 15805284
DOI: 10.1158/0008-5472.CAN-04-3227

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.PMID 15805284Read ↗

Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma.Semantic proximity Read ↗

Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.Semantic proximity Read ↗

Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma.Semantic proximity Read ↗

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus MutantSemantic proximity Read ↗

Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cellsSemantic proximity Read ↗

Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like CellsSemantic proximity Read ↗

Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy.Semantic proximity Read ↗

Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma.Semantic proximity Read ↗

A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors.Semantic proximity Read ↗

Zika virus has oncolytic activity against glioblastoma stem cellsSemantic proximity Read ↗

Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved TolerabilitySemantic proximity Read ↗

Oncolytic Virus Therapy for Glioblastoma MultiformeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.